Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB2004-HR: Topotecan in High-Risk Neuroblastoma
NCT03042429Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Jan 2007
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of topotecan in neuroblastoma (2 arms), sponsored by University of Cologne. Primary endpoint: Event Free Survival at 9 years. Started Jan 2007; status: completed.
02
Drugs
topotecan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03042429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042429.